Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables (2021 - 2025)

Kiniksa Pharmaceuticals International's Receivables history spans 5 years, with the latest figure at $15.6 million for Q4 2025.

  • For Q4 2025, Receivables fell 62.63% year-over-year to $15.6 million; the TTM value through Dec 2025 reached $15.6 million, down 62.63%, while the annual FY2025 figure was $15.6 million, 62.63% down from the prior year.
  • Receivables reached $15.6 million in Q4 2025 per KNSA's latest filing, down from $51.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $51.7 million in Q3 2025 to a low of $2.6 million in Q2 2021.
  • Average Receivables over 5 years is $19.9 million, with a median of $20.3 million recorded in 2022.
  • Peak YoY movement for Receivables: crashed 74.78% in 2023, then surged 718.41% in 2024.
  • A 5-year view of Receivables shows it stood at $4.0 million in 2021, then surged by 409.81% to $20.3 million in 2022, then grew by 4.68% to $21.3 million in 2023, then surged by 96.2% to $41.7 million in 2024, then tumbled by 62.63% to $15.6 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Receivables are $15.6 million (Q4 2025), $51.7 million (Q3 2025), and $31.9 million (Q2 2025).